Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25680841 | 0.78 | NPSR1 (0.44) | P2RX3P2RX2MAPTRAB9A | |
| SCHEMBL13309400 | 0.76 | P2RX3 (0.39) | P2RX3P2RX2MAPTRAB9A | |
| SCHEMBL23868211 | 0.70 | SMN1; SMN2 (0.59) | HSD17B10MAPTRAB9A | |
| SCHEMBL22281955 | 0.69 | ALDH1A1 (0.50) | — | |
| SCHEMBL8202022 | 0.68 | EPHX2 (0.45) | MAPTRAB9A | |
| SCHEMBL3696695 | 0.66 | EGLN1 (0.43) | HSD17B10TDP1MAPTRAB9A | |
| SCHEMBL13542055 | 0.66 | KMT2A (0.63) | HSD17B10 | |
| SCHEMBL824789 | 0.66 | — | — | |
| SCHEMBL10093682 | 0.64 | KDM4E (0.33) | — | |
| SCHEMBL12457570 | 0.64 | HSP90AB1 (0.41) | HSD17B10MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118507-A1 | Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4--Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives | PIERRE FABRE MEDICAMENT (FR) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118507-A1 | Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4--Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives | DNMT1, MCM4, MCM5 | P2RX3 1415/4885P2RX2 1652/4885HSD17B10 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.